Synergistic activity between both azlocillin and meziocillin and aminoglycosides or cefazolin could be demonstrated by checkerboard dilution, isobologram, and killing curve techniques. Aziocilhin and mezlocillin combined with gentamicin, netilmicin, or amikacin were synergistic against Escherichia coli, Klebsiella, Citrobacter, Enterobacter, Serratia, and indole-positive Proteus. Synergy was observed with isolates that were susceptible or resistant to azlocillin or mezlocillin. Synergy was seen most often when azlocillin or mezlocillin were combined with amikacin, gentamicin, or netilmicin against Pseudomonas aeruginosa. The combination of mezlocillin and an aminoglycoside produced synergy more often than did carbenicillin plus an aminoglycoside. No antagonism was seen when aminoglycoside antibiotics were combined with azlocillin or mezlocillin. Cefazolin was synergistic against Pseudomonas, Providencia, P. mirabilis, indole-positive Proteus, Citrobacter, Klebsiella, and Escherichia coli, when combined with azlocillin or mezlocillin. However, the combination of either agent with cefazolin was antagonistic when tested against selected indole-positive Proteus and Enterobacter isolates. Gram-negative bacilli now account for the majority of infections in hospitalized patients. Although carbenicillin and more recently ticarcillin (9, 11) have contributed significantly to our ability to cure such infections, the high concentrations of both agents needed clinically has prompted a continued search for new and more active agents. Aminoglycosides have been developed that are active against resistant Pseudomonas, and these agents are used widely in the therapy of sepsis in both normal and immunocompromised hosts. Clinical studies have suggested that use of aminoglycosides alone in neutropenic patients will not result in cure (11). Hence, penicillins and aminoglycosides are usually combined when treating patients with suspected sepsis or when it is felt that synergy between the two agents might be desirable. Recently, concem over possible renal toxicity due to the combination of aminoglycosides and cephalosporins has increased the combined clinical use of cephalosporin antibiotics and broad-spectrum penicillins. Thus, we evaluated the synergistic activity of azlocillin and mezlocillin when combined with either aminoglycoside antibiotics or cephalosporin agents. (These studies were t Address reprint requests to:
presented in part at the 76th Annual Meeting of the American Society for Microbiology, Atlantic City, 1976, and at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1976.) MATERIALS AND METHODS Azlocillin and mezlocillin were obtained from Delbay Pharmaceuticals. Netilmicin and gentamicin were supplied by Schering Corp., and amikacin was supplied by Bristol Laboratories. Carbenicillin and ticarcillin were gifts from Beecham Laboratories. The other antibiotics were obtained from their individual manufacturer. All antibiotic dilutions were prepared fresh daily in sterile medium or distilled water. All bacterial isolates tested were obtained from patients hospitalized at Columbia-Presbyterian Medical Center in New York City.
Synergy tests. Synergy tests were performed by three methods (4, 7) . First, a checkerboard twofolddilution method with both antibiotics was used to construct isobolograms. Second, one antibiotic was added in a concentration equivalent to one-fourth its minimal inhibitory concentration (MIC) to increasing concentrations of the other antibiotic. Third, killing curve techniques were used to evaluate the combination of both antibiotics in concentrations equivalent to one-fourth of their MICs. The criteria of synergy have been determined as described previously (4 the MICs of each drug used singly was tested alone and in combination at 37°C, and samples were removed and diluted in broth and plated on agar as previously described (4) .
RESULTS
Isobolograms demonstrating the synergy between azlocillin and gentamicin or mezlocillin and gentamicin are shown in Fig. 1 Combination of mezlocillin and netilmicin against a strain of Providencia stuartii that contained enzymes inactivating both antibiotics produced a two-log decrease in CFU by 6 h (Fig.  3) , but the organism began to regrow and reached the original inoculum size by 24 h. However, this combination produced a fourfold reduction in CFU compared with that produced by mezlocillin or netilmicin alone. Figure 4 shows the activity of azlocillin and of mezlocillin alone and in combination with gentamicin in one-fourth the MICs against selected Pseudomonas aeruginosa, Klebsiella, and E. coli isolates. There were 15 of the 45 isolates tested that were inhibited by the synergistic azlocillin-gentamicin combination at a concentration of azlocillin that can be easily achieved in humans. Eight isolates of E. coli, six highly resistant to azlocillin, were not synergistically inhibited. However, three Serratia isolates highly resistant to azlocillin were inhibited by the combination. When mezlocillin and gentamicin were combined, only 11 isolates of the 45 tested were synergistically inhibited. E. coli highly resistant to both agents was not inhibited.
The activity of the combination of azlocillin
Isobolograms showing synergy of (A) azlocillin-gentamicin against E. coli 2162 (A) and Kiebsiella 3011^) and of (B) meziocillin-gentamicin against E. coli 2526 C)), and P. aeruginosa T 121 (4) . MICs ofnetilmicin and aziocillin against E. coli 2145 were 2.5 pg/ml and 100 pg/ml, respectively. MICs of cefazolin and aziocilin against P. morganii 3075 were 200 pg/ml and 12.5 pg/ml, respectively. with netilmicin and mezlocillin with netilmicin against Pseudomonas, Providencia, Proteus mirabilis, P. rettgeri, P. morganii, P. vulgaris, Enterobacter, Citrobacter, Klebsiella, and E. coli is shown in Fig. 5 . Synergistic activity by the azlocillin-netilmicin combination was observed with 28% of isolates, and by the mezlocillin-netilmicin combination it was observed with 61%. Synergy between azlocillin and netilmicin was investigated against 133 isolates. Synergy was observed with 7% of E. coli, 8% In contrast to the preceding findings when the ureidopenicillins were combined with aminoglycosides, combination with cefazolin ( Fig. 6 ) produced synergy for the azlocillin-cefazolin combination for 32% of isolates and antagonism for 16%, and for mezlocillin-cefazolin synergy was produced with 32% of isolates which included P. vulgaris, P. morganii, and Enterobacter. This antagonism of the combination of the ureidopenicillins and cefazolin was not limited to any particular ratio of combinations of the antibiotics. gentamicin. Against azlocillin-susceptible isolates, combination with amikacin was synergistic for 40%, combination with gentamicin was synergistic for 56%, and combination with netilmicin was synergistic for 72% ( emergence of drug-resistant microorganisms membrane to ribosomal sites (Fu and Neu, . The combination of two antibiotics has mitted for publication), could be overcome. Isoproved useful in enhancing the activity of both lates that showed wide aminoglycoside resistantibiotics due to synergistic action and in pre-ance, but contained no inactivating enzymes, venting the development of resistant organisms. were synergistically inhibited by the combinaThe present studies demonstrated that azlo-tion of aminoglycosides and penicillins that discillin and mezlocillin, when combined with ami-rupted the cell wall and apparently facilitated noglycoside antibiotics and cefazohin, not only the transport of aminoglycosides to the riboshowed synergistic action but also were active somal sites. This suggests the usefulness of this against organisms that were resistant to both of combination in inhibiting these isolates that are the antibiotics tested. There was evidence that aminoglycoside resistant due to a permeability aminolgycoside resistance, whether due to inac-barrier. tivating enzymes or to a failure of the aminoglyComparative synergistic studies showed that cosides to be transported across the cytoplasmic the azlocillin-amikacin combination was the most active against P. aeruginosa, although azlocillin-netilmicin was synergistic for a greater number of isolates.
The /8-lactamase inhibition theory has been applied to infections due to gram-negative ba- In view ofthese studies, these compounds may offer clinical advantage in view of their greater in vitro activity compared with ampicillin, carbenicillin, and cefazolin and particularly because of the high degree of synergy when they are combined with aminoglycosides. The clinical significance of this study should be further evaluated in animal models and clinical trials.
